Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
- Lead sponsor
- Xencor, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 10, 2018
- Completion date
- September 6, 2022
- Enrollment
- 150 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.
basal cell carcinoma, breast carcinoma, castration-resistant prostate carcinoma, cervical cancer, cholangiocarcinoma, colorectal carcinoma, endometrial carcinoma, fallopian tube carcinoma, gastric or gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, malignant adnexal neoplasms, melanoma, mesothelioma, nasopharyngeal carcinoma, neuroendocrine carcinoma, non-small cell lung carcinoma, non-squamous cell salivary gland carcinoma, ovarian carcinoma, renal cell carcinoma, small cell lung carcinoma, solid tumors with published evidence of anti-tumor activity with anti-pd1/pdl1 and/or anti-ctla4-directed therapy, squamous cell carcinoma of the anus, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the penis, thymic carcinoma, thymoma, urothelial carcinoma, vulvar carcinoma